bezlotoxumab cost
This resulted in 0.16 and 0.28 incremental discounted age-weighted QALYs gained per-patient for subgroup 1 and subgroup 2, respectively. The threshold price at which bezlotoxumab is cost-effective at the $100,000/QALY threshold is $17,188 and $30,118 for subgroup 1 and subgroup 2, respectively. Key influential parameters include CDI-specific mortality, cost of a rCDI episode, and underlying recurrence rate.